A Form 4 filed with the SEC on August 12, 2026 discloses that Axogen, Inc. director Amy McBride-Wendell exercised stock options and sold 13,353 shares of common stock on August 11, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Amy McBride-Wendell acquired 13,353 shares of Axogen common stock via exercise of an employee stock option at $14.85 per share on August 11, 2026.
  • Share sale: The same 13,353 shares were sold on August 11, 2026, at a weighted average price of $48.423 per share, with individual transactions ranging from $47.82 to $49.02.
  • 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2026.
  • Remaining ownership: Following the transactions, McBride-Wendell directly holds 107,976 shares of Axogen common stock.
  • Options fully vested: The underlying stock option was fully vested on May 14, 2018, according to the filing.
  • Derivative position closed: After the exercise, McBride-Wendell holds 0 shares under that employee stock option, which had an expiration date of June 1, 2027.

Axogen Director Exercises and Sells Options Under Scheduled Trading Plan

According to the Form 4 filed on August 12, 2026, Amy McBride-Wendell, a director of Axogen, Inc. (NASDAQ:AXGN), reported two linked transactions dated August 11, 2026. First, she exercised an employee stock option covering 13,353 shares at the option's exercise price of $14.85 per share, bringing her directly held share total to 121,329 shares. Immediately following, she disposed of all 13,353 of those shares in the open market.

The filing notes that the sale was executed under a Rule 10b5-1 trading plan that McBride-Wendell adopted on May 12, 2026. The reported sale price of $48.423 is a weighted average; the filing discloses that individual transactions occurred at prices ranging from $47.82 to $49.02 per share. The filing states that full information on the number of shares sold at each price is available upon request to the issuer, any security holder, or SEC staff.

Following both transactions, McBride-Wendell directly holds 107,976 shares of Axogen common stock, as reported in Table I of the filing. The employee stock option involved was fully vested as of May 14, 2018, and carried an expiration date of June 1, 2027; its remaining balance is now zero. The Form 4 was signed by Marc Began as attorney-in-fact for Amy McBride-Wendell.

What Was Disclosed

The filing discloses an option exercise and same-day stock sale by an Axogen director on August 11, 2026, conducted under a pre-scheduled 10b5-1 plan, resulting in direct ownership of 107,976 shares of Axogen common stock.